Cytokinetics, Inc.
Cytokinetics Reports Third Quarter 2025 Financial Results
Summary
On November 5, 2025, Cytokinetics, Incorporated announced its financial results for the third quarter of 2025. The company reported total revenues of $1.9 million, up from $0.5 million in the same period last year. Research and development expenses increased to $99.2 million, while general and administrative expenses rose to $69.5 million. The net loss for Q3 2025 was $306.2 million, compared to a net loss of $160.5 million in Q3 2024. The company also provided an update on its clinical trials and commercial readiness activities for aficamten.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement